Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144794 · ClinicalTrials.gov registry record
Mucopolysaccharidosis I (MPS I) Registry
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 1,406
- Enrollment target
NCT00144794 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,406 participants.
The verdict
NCT00144794 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 1,406 participants
- Enrollment target
Study Summary
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) * To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I * To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,406 participants |
| Start Date | 2003-11-20 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144794
The ClinicalTrials.gov registry entry for NCT00144794 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00144794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144794 about?
NCT00144794 is a clinical study titled "Mucopolysaccharidosis I (MPS I) Registry". The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses ...
What is the current status of trial NCT00144794?
This trial is currently completed. The enrollment target is 1,406 participants. The study started on 2003-11-20. Estimated completion is 2024-12-31.
Who is sponsoring clinical trial NCT00144794?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.